Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001562180-25-000496
Filing Date
2025-01-23
Accepted
2025-01-23 19:56:40
Documents
2
Period of Report
2025-01-21

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 3  
1 PRIMARY DOCUMENT primarydocument.xml 3 1736
2 BLAUSTEIN POA blaustein-poa.txt EX-99 1991
  Complete submission text file 0001562180-25-000496.txt   5104
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Issuer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1715 38TH STREET BOULDER CO 80301
Business Address
Blaustein Robert (Reporting) CIK: 0002053149 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40236 | Film No.: 25551327